AGNG
Global X Aging Population ETF
Global X Longevity Thematic ETF is an exchange-traded fund incorporated in the USA. The Fund seeks to track the performance of the Indxx Global Longevity Thematic Index.
Global
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 84.6 M
ASSETS UNDER MGMT
50 bp
EXPENSES
Fund Basics
| Inception date | May 09, 2016 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| UCB SA | 4.9 % |
| JOHNSON & JOHNSON | 3.8 % |
| ASTRAZENECA PLC | 3.8 % |
| MERCK & CO. INC. | 3.7 % |
| WELLTOWER, INC. | 3.7 % |
| ROCHE HOLDING AG-BR | 3.3 % |
| REGENERON PHARMACEUTICALS | 3.3 % |
| ELI LILLY & CO | 3.1 % |
| AMGEN INC | 3.0 % |
| CHUGAI PHARMACEUTICAL CO LTD | 3.0 % |
Constituent Breakdown
| Number of holdings | 79 |
| Herfindahl-Hirschman Index | 235 |
| Wgt avg mkt cap (mns) | $125,389 |
| Large cap (>$10bn) | 86.7% |
| Mid cap ($2-10bn) | 9.3% |
| Small cap (<$2bn) | 4.1% |
| Developed mkts. | 92.2% |
| Emerging mkts. | 7.9% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 54.0 % |
 |
SWITZERLAND | 10.6 % |
 |
JAPAN | 6.8 % |
 |
CHINA | 5.6 % |
 |
BRITAIN | 5.5 % |
 |
BELGIUM | 5.2 % |
 |
DENMARK | 3.5 % |
 |
IRELAND | 2.6 % |
 |
SOUTH KOREA | 2.3 % |
 |
GERMANY | 1.0 % |
Historical Performance
Standardized Performance (as of 03/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -0.8% | 13.7% | 8.7% | 9.9% | 5.1% | -- | -- | 8.8% |
| Dividend Yield | 0.0% | 1.1% | 1.0% | 1.0% | 0.8% | -- | -- | 0.9% |
| Total Returns | -0.8% | 14.8% | 9.7% | 10.9% | 5.9% | -- | -- | 9.8% | Ann. Volatility | 14.5% | 16.0% | 14.2% | 13.4% | 15.1% | -- | -- | 17.2% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.56 | 45% |
| MSCI EAFE | 0.72 | 63% |
| MSCI Emg Mkts | 0.51 | 41% |
Liquidity Measures
| Avg. volume (000) | 16 |
| ADV traded (mns) | $1 |
| Turnover | 0.7% |
| Avg. Bid/Ask (% of price) | 0.36% |
Technical Indicators
| 30d moving avg. (EMA) | $36.02 |
| Relative strength (RSI) | 49 |
| MACD/Signal | -0.10/-0.32 |
| Bollinger Bands (Upper/Lower) | $36.75/$34.18 |
| Short interest (% of AUM) | 1.1% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. AGNG |
Expenses vs. AGNG |
ALTAR Score™ vs. AGNG |
|---|---|---|---|---|
| HRTS | Tema Heart & Health ETF | 34.7% | +25 bp | -1.3% |
| IXJ | iShares Global Healthcare ETF | 33.7% | -8 bp | +2.3% |
| IYH | iShares U.S. Healthcare ETF | 29.3% | -10 bp | +1.9% |
| BMED | Future Health ETF | 28.5% | +35 bp | -3.6% |
| XLV | Health Care Select Sector SPDR | 28.5% | -42 bp | +2.6% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 28.4% | +10 bp | +3.0% |
| FHLC | Fidelity MSCI Health Care Index ETF | 28.0% | -42 bp | +1.4% |
| VHT | Vanguard Health Care ETF | 27.9% | -41 bp | +1.1% |
| JDOC | JPMorgan Healthcare Leaders ETF | 27.7% | +15 bp | -0.6% |
| CANC | Tema Oncology ETF | 27.7% | +25 bp | -6.5% |
Risk and Returns: AGNG vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 4/17/2026
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Historical Valuation Trends Sample data. Subscribe for access.
SHOWING:
Price-to-Earnings
Price-to-Earnings
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
4.5%
ALTAR SCORE™
53rd
PERCENTILE
NEUTRAL
ETFRC RATING
There are 586 funds in the Global Equity category with an average
ALTAR Score™ of 4.4% and a standard deviation
of 2.6%. AGNG's ALTAR Score™ is approximately 0.1 standard
deviations above the category average. This places AGNG in the 53rd percentile
among funds in the category.
Sell-Side Consensus
$42.94
PRICE TARGET
+18.3%
UPSIDE